Abstract:Abstract Introduction: Despite initial efficacy, most patients (pts) with HR+/HER2– advanced breast cancer (BC) eventually progress on endocrine therapy (ET) plus a CDK4/6 inhibitor (CDK4/6i). In preclinical models, resistance to ET + CDK4/6i can be overcome by concomitant inhibition of CDK2. Therefore, simultaneous inhibition of CDK2/4/6 may provide a new therapeutic strategy to prolong clinical benefit. This first-in-human dose escalation/expansion study (NCT03519178) is evaluating the safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary antitumor activity of the first-in-class selective CDK2/4/6 inhibitor PF-06873600 (PF-3600) as monotherapy and combined with ET. The results of Part 1 monotherapy dose escalation and initial combination with ET are presented.Methods: This is a phase 1/2a, open-label, non-randomized, study of PF-3600 as monotherapy and combined with letrozole or fulvestrant (F). Pts with locally advanced/metastatic HR+/HER2– BC whose tumor progressed on previous ET + CDK4/6i and with ≤2 prior lines of chemotherapy (Cx), triple-negative breast cancer (TNBC) with ≤2 prior lines of Cx, and platinum-resistant ovarian cancer (OVCA) with ≤3 prior lines of treatment (Tx) were eligible for Part 1 dose escalation. Pts received escalating doses of PF-3600 (1–50 mg) BID orally. Dose escalation followed the modified toxicity probability interval method. Tx continued until disease progression, toxicity requiring discontinuation or pt withdrawal. Primary objectives for Part 1 were to evaluate safety including dose-limiting toxicities (DLTs) in the 1st 28-day cycle, adverse events (AEs), and laboratory abnormalities; and to select the recommended dose for expansion (RDE) in combination with ET. Results: As of 24 June 2021, 67 pts (HR+/HER2– BC, n=59; TNBC, n=2; OVCA, n=6) received PF-3600 (n=58) or PF-3600 + F (n=9). In the PF-3600 group, 22 (38%) and 36 (62%) pts had ECOG performance status (PS) 0 and 1, respectively. In the PF-3600 + F group, 6 (67%) and 3 (33%) pts had ECOG PS 0 and 1, respectively. The median (range) number of prior Tx in the metastatic setting was 4.0 (1, 8) for PF-3600 and 4.0 (3, 6) for PF-3600 + F. The most frequently reported treatment-related AEs (all grade/grade ≥3) for PF-3600 alone and PF-3600 + F, respectively, were nausea (50%/0% and 67%/0%), anemia (38%/14% and 44%/11%) and neutropenia (29%/16% and 22%/11%). Six (13%) of 48 DLT-evaluable pts treated with monotherapy had DLTs; all occurred at the highest doses (35 and 50 mg BID). At the RDE of 25 mg BID (PF-3600 alone, n=17; PF-3600 + F, n=9), there were no DLTs. PF-3600 exposure increased with dose, was not significantly impacted by F and at the RDE remained above the preclinical efficacious concentrations in most of the tested models for >70% of the dosing interval. The disease control rate was 48% (28/58, PF-3600) and 67% (6/9, PF-3600 + F) including 3 pts who remained stable for >13 mos with one ongoing for >28 mos. Three heavily pre-treated pts with HR+/HER2– BC (including prior ET + CDK4/6i and Cx) treated with PF-3600 alone had partial responses (2 confirmed), including 1 pt who remained on Tx for >13 mos. Modulation of cell cycle PD biomarkers (pRb and Ki-67) in paired tumor biopsies was observed. Data are not final and subject to change. Updated data will be presented.Conclusions: PF-3600 can be combined with ET with a manageable AE profile and demonstrates promising preliminary antitumor activity in heavily pretreated pts, including those with HR+/HER2– BC progressing on ET + CDK4/6i and Cx. Dose expansion in combination with ET in pts with HR+/HER2– BC with and without prior CDK4/6i Tx is ongoing. Citation Format: Timothy A. Yap, Cynthia Basu, Jonathan W. Goldman, Michael Gordon, Erika Hamilton, Adrianne Kelly, Feng Liu, Allison R. Moreau, Heather Neumann, Kyriakos Papadopoulos, Hope S. Rugo, Geoffrey I. Shapiro, Shaveta Vinayak, Li Zhou, Komal Jhaveri. A first-in-human phase 1/2a dose escalation/expansion study of the first-in-class CDK2/4/6 inhibitor PF-06873600 alone or with endocrine therapy in patients with breast or ovarian cancer [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P5-16-06.

First-in-human phase 1/2a study of the first-in-class, next-generation CDK4-selective inhibitor PF-07220060 + endocrine therapy (ET): Updated safety data in patients with HR+/HER2− mBC.

First-in-human first-in-class phase 1/2a study of the next generation CDK4-selective inhibitor PF-07220060 in patients (pts) with advanced solid tumors, enriched for HR+ HER2- mBC who progressed on prior CDK4/6 inhibitors and endocrine therapy.

Abstract P5-16-06: A first-in-human phase 1/2a dose escalation/expansion study of the first-in-class CDK2/4/6 inhibitor PF-06873600 alone or with endocrine therapy in patients with breast or ovarian cancer

First-in-human phase 1/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4/6 inhibitor resistant HR+/HER2- breast cancer.

International phase 3 clinical trial evaluating PF-07220060 plus fulvestrant in patients with HR+/HER2− advanced/metastatic breast cancer with progression after a prior CDK4/6 inhibitor.

Abstract PS15-02: A Phase Ⅰb Study of D-0502 as Monotherapy for Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer: Results from the Dose-Expansion Stage

The CDK4/6 inhibitor FCN-437c plus letrozole for the treatment of HR+/HER2advanced breast cancer: Updated results from a phase 1b study.

Abstract CT117: Phase I dose-escalation and dose-expansion trial of CDK4/6 inhibitor FCN-437c in Chinese female patients with ER+HER2- advanced breast cancer (ABC)

Safety, Pharmacokinetics, and Preliminary Activity of CDK4/6 Inhibitor FCN-437c in Chinese Female Patients with HR+HER2- Advanced Breast Cancer (ABC) From Phase Ia Study

Phase la study of the CDK4/6 inhibitor, FCN-437c, in Chinese patients with HR+/HER2-advanced breast cancer

A phase 1 dose expansion study of a first-in-class KAT6 inhibitor (PF-07248144) in patients with advanced or metastatic ER+ HER2− breast cancer.

Phase 1a study of the CDK4/6 inhibitor, FCN-437c, in Chinese patients with HR + /HER2- advanced breast cancer

Abstract 5709: PF-07104091, a first-in-class CDK2-selective inhibitor for the treatment of HR+/HER2- breast cancer and CCNE1high ovarian cancer

Cyclin-dependent Kinase 4/6 (CDK4/6) Inhibitor SHR6390 Combined with Pyrotinib and Letrozole in Patients with Human Epidermal Growth Factor Receptor 2-Positive (HER2+), Hormone Receptor Positive (HR+) Metastatic Breast Cancer (MBC): Phase Ib Study Results.

Abstract P4-01-21: Phase 2 Study of the CDK4/6 Inhibitor FCN-437c in Combination With Fulvestrant or Letrozole and Goserelin in Patients With HR+, HER2– Advanced Breast Cancer

Abstract 595: Preclinical development of the CDK4 selective inhibitor PF-07220060: Increased CDK4 versus CDK6 inhibition leads to improved anti-tumor efficacy at therapeutic concentrations

A First-in-human, Open Label, Multiple Dose, Dose Escalation, and Cohort Expansion Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of BB-1701 in Patients with Locally Advanced/metastatic HER2-expressing Solid Tumors

The CDK4/6 inhibitor FCN-437c plus letrozole for the treatment of HR+/HER2– advanced breast cancer: Updated results from a phase 1b study.

Abstract PO4-27-05: A phase I open-label dose escalation trial of FWD1802 as monotherapy and in combination with palbociclib in patients with ER+/HER2- unresectable locally advanced or metastatic breast cancer with or without ESR1 mutations

Abstract PS17-08: A Phase Ib Study to Evaluate the Efficacy and Safety of Afuresertib Plus Fulvestrant in Patients with Locally Advanced or Metastatic HR+/HER2- Breast Cancer Who Failed Standard of Care Therapies

Abstract B159: A first-in-human study of CDK9 inhibitor KB-0742 demonstrates evidence of tolerability and clinical activity